نتایج جستجو برای: botox
تعداد نتایج: 636 فیلتر نتایج به سال:
BACKGROUND Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. OBJECTIVE To determine the amount of BoNT/A protein present in pharmaceutical preparations...
AIM To confirm and compare the therapeutic efficacies and adverse effects of Chinese botulinum toxin type A (CBTX-A, Lanzhou Biological Products Institute, China) and current Botox (Allergan Inc., CA, USA) in the treatment of blepharospasm (BS) and hemifacial spasm (HFS). MATERIAL AND METHODS We performed an open, prospective, comparative trial comparing CBTX-A and Botox for the treatment of ...
Treatment of tendon injuries often involves immobilization. However, immobilization might not prevent mild involuntary isometric muscle contraction. The effect of weak forces on tendon healing is therefore of clinical interest. Studies of tendon healing with various methods for load reduction in rat Achilles tendon models show a consistent reduction in tendon strength by at least half, compared...
BACKGROUND Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing these formulations in spasticity treatment. The aim of our study was to compare the efficacy and safety of Prosigne® ...
Lack of Interchangeability Between Botulinum Toxin Products The potency Units of BOTOX® are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX® cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other speci...
We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of cervical dystonia (CD). A Dysport/Botox ratio of lower than 3:1 was suggested as a more appropriate conversion ratio, considering its higher efficacy and more frequent incidence of adverse effects not only in the treatment of...
s of Botulinum Toxin Type A in Migraine Headache In 2003, Blumenfeld (32) reported on the efficacy of BT-A in reducing headache frequency and intensity in a retrospective, open-label analysis that included 271 patients. All participants had disabling, chronic migraine. BT-A was administered at an average, fixed dose of 63.2 U either at a fixed site or in a pattern that followed the pain. A resp...
INTRODUCTION: Marketing disinformation has confused physicians about the comparative safety and efficacy of Botox® and Xeomin®. Comparative studies to date were in different patients. Variations of onset and duration are significant in different patients using the same product. Thus comparing the two products is not reliable. In this study, Xeomin® was injected in one side of the forehead and B...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید